FDA Approves AbbVie’s Hepatitis C Drug

The Food and Drug Administration approved the drug Technivie to treat chronic hepatitis C virus (HCV) genotype 4 infections.

Technivie (ombitasvir, paritaprevir, and ritonavir tablets), marketed by AbbVie Inc., is the first all-oral drug to be approved in the U.S. for adults with genotype 4 chronic HCV that doesn’t need to be used in conjunction with interferon, another HCV drug, according to a July 24 statement from the FDA.

Technivie was approved to be used in conjunction with ribavirin, a nucleoside analogue medication that works to stop the virus that causes hepatitis C from spreading inside the body.

The effectiveness ...